RELATING TO WORKERS' COMPENSATION.
SB2751 amends Hawaii’s workers’ compensation prescription drug rules, with a focus on compounded medications and physician dispensing. The bill defines “compounded prescription drug” by reference to federal Food, Drug, and Cosmetic Act section 503A standards, tying the state definition to federal compounding requirements and quality controls. It also requires non-FDA-approved drugs, including compounds, to be clearly identified on treatment plans and billing records, and to be supported by a statement of medical necessity showing why the compound is needed instead of an FDA-approved drug with similar therapeutic effect.
The measure also changes how prescription drugs are dispensed after a work injury. Physicians may dispense prescription drugs only for the first 30 days after the industrial injury, after which all prescription drugs must be obtained through the employer’s pharmacy benefit manager. The bill preserves existing reimbursement rules for prescription drugs and compounded drugs, including payment formulas based on average wholesale price and National Drug Code information, and it continues to allow generic substitution unless the prescribing physician certifies that the injured worker cannot tolerate the generic alternative. The bill is set to take effect on January 1, 2077, and applies prospectively without affecting already matured rights, penalties, or proceedings.
In terms of legal impact, SB2751 would amend section 386-21.7 of the Hawaii Revised Statutes governing workers’ compensation pharmaceuticals. It would add a statutory definition for compounded prescription drugs, impose new documentation and billing requirements for compounds and other non-FDA-approved drugs, and shift post-initial-injury dispensing to the employer’s pharmacy benefit manager. These changes would affect injured workers, prescribing physicians, pharmacies, employers, carriers, and pharmacy benefit managers by tightening oversight and potentially reducing disputes over compound-drug reimbursement and dispensing practices.
The overall sentiment reflected in the available legislative history appears generally supportive but cautious. The bill passed both Senate Labor and Technology and Senate Health and Human Services with amendments and no recorded dissent in those votes, suggesting broad agreement on the need for clearer rules and stronger controls. At the same time, the measure was later deferred by the Senate Judiciary Committee, indicating that legal or policy concerns remained unresolved at that stage.
The main points of contention likely center on the balance between access to individualized treatment and cost control. Supporters emphasize patient safety, transparency, and alignment with federal compounding standards, while potential critics may be concerned that the 30-day physician-dispensing limit, mandatory use of the employer’s pharmacy benefit manager, and stricter compound documentation requirements could restrict treatment options or create administrative burdens for providers and injured workers. The compound-drug reimbursement and identification rules also suggest an effort to curb questionable billing practices, which may be a source of debate among stakeholders with different views on utilization management and medical necessity standards.
SB2751 would amend Hawaii Revised Statutes section 386-21.7 governing workers’ compensation prescription drugs. It would add a statutory definition of “compounded prescription drug” tied to federal compounding law, require compounds and other non-FDA-approved drugs to be identified and justified in treatment plans and billing, and limit physician dispensing to 30 days after an industrial injury before requiring use of the employer’s pharmacy benefit manager. The bill would affect injured workers, physicians, pharmacies, employers, carriers, and pharmacy benefit managers by tightening documentation, reimbursement, and dispensing rules for workers’ compensation pharmaceuticals.
The available vote history suggests the bill was received positively in policy committees, with unanimous passage as amended in both Senate Labor and Technology and Senate Health and Human Services. However, the later deferral by the Senate Judiciary Committee indicates that support was not fully settled and that legal or implementation concerns may have remained. Overall, the sentiment appears favorable toward greater transparency and control, but with some caution about the bill’s legal and operational effects.
The main areas of contention are likely the bill’s restrictions on physician dispensing, the requirement that post-30-day prescriptions be routed through the employer’s pharmacy benefit manager, and the added documentation burden for compounded and other non-FDA-approved drugs. Supporters appear to prioritize cost containment, transparency, and alignment with federal compounding standards, while opponents or skeptics may worry about reduced flexibility in treating injured workers, delays in care, and administrative complexity for providers. The Judiciary Committee’s deferral suggests there may also have been unresolved legal questions about the scope or enforceability of the new requirements.